Leading Korean CRO using Vault eTMF, Vault CTMS, and Veeva SiteVault Free for increased efficiency and collaboration with sponsors

Veeva Systems (NYSE: VEEV) announced that LSK Global Pharma Services Co. Ltd, a leading Korean contract research organization (CRO), has adopted Veeva Vault eTMF, Veeva Vault CTMS, and Veeva SiteVault Free. With Veeva Vault Clinical applications, LSK Global PS can streamline trial management and remotely collaborate with study monitors for document review and verification.

“As a leading CRO, our aim is to run faster, more efficient trials,” said Young-Jack Lee, Ph.D. and president of LSK Global Pharma Services Co. Ltd. “Veeva Vault Clinical applications enable us to operate remote trials, provides full visibility into end-to-end trial activities, and improves our collaboration with sponsors.”

Vault eTMF (electronic trial master file) and Vault CTMS (clinical trial management system) are part of the Veeva Vault Clinical Suite, the industry’s first cloud platform that unifies clinical data management and operations. SiteVault Free simplifies research by replacing paper-based processes. Together, these applications enable LSK Global PS to accelerate trial execution and deliver real-time visibility within a short timeframe.

“We are proud to support LSK Global PS,” said Chris Shim, Veeva vice president of Vault R&D and Quality Asia. “With Veeva Vault Clinical applications, LSK Global PS is innovating their clinical trial processes and running faster, high-quality studies.”

To learn how Vault Clinical Suite is helping CROs to streamline clinical trial processes and information exchange, visit veeva.com/Clinical.

About LSK Global Pharma Services Co., Ltd

LSK Global Pharma Services Co., Ltd.(http://www.lskglobal.com/), established in 2000 in Korea, is the nation’s largest integrated contract research organization (CRO) that has provided therapeutic area-specific services across oncology, cardiovascular disease and endocrinology.

LSK Global PS is a full-service CRO encompassing all of the major areas of clinical research, including clinical trials from phase I to IV, investigator-led clinical studies, PMS (post-marketing surveillance) studies, safety studies and observational studies. In addition, it provides consulting services for new drug development, regulatory affairs, study start-up, medical writing and research, clinical operation, project management, data management, statistical analysis, pharmacovigilance (PV), epidemiological research, and quality assurance.

LSK Global PS has conducted 1,277 clinical studies, including 144 global clinical studies and 110 IND studies, since its foundation (as of December 2020). It is the first Korean CRO to win a contract for an FIH (first-in-human) phase I study of an anticancer agent from a multinational pharmaceutical company, an achievement that was especially meaningful because LSK Global PS was competing against large global CROs to win this contract. Also, LSK Global PS has successfully completed a large-scale global phase III trial for an anticancer agent, which was conducted in 95 sites in 12 countries including the US, Europe, and Asia.

In March 2017, LSK Global PS became the first Korean CRO which acquired the ‘ISO (International Organization for Standardization) 9001:2015’ certification for Quality Management Systems in the entire areas of services relevant with clinical trials. In December 2019, it became the first Korean CRO to acquire the ‘ISO 37001’ certification for Anti-Bribery Management Systems.

LSK Global PS also became the first Korean CRO to establish a PV branch office in Europe in May 2019 and a DM (Data Management) branch office in Taiwan in February 2020.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210307005011/en/

Post a Comment

Previous Post Next Post
Like this content? Sign up for our daily newsletter to get latest updates.